ALPHATEC HOLDINGS, INC. (NASDAQ:ATEC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ALPHATEC HOLDINGS, INC. (NASDAQ:ATEC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Story continues below

Effective June 17, 2020, the Board of Directors (“Board”) of Alphatec Holdings, Inc. (the “Company”) increased the number of directors to serve on the Board to twelve members and appointed David Pelizzon to serve as a director for a term commencing on June 17, 2020, immediately following the 2020 Annual Meeting of Stockholders of the Company, and expiring at the Annual Meeting of Stockholders of the Company in 2021.  

Mr. Pelizzon will receive annual equity compensation in accordance with the Company’s standard remuneration for its non-employee directors, as revised by the Compensation Committee of the Board effective as of June 17, 2020, which provides that non-employee directors shall receive an annual Restricted Stock Unit (“RSU”) award with a grant value of $100,000 for service on the Board (the “Board Grant”) and, as applicable, an annual RSU award(s) with a grant value of (i) $25,000 to each non-employee director that serves as Chair or Lead Director of the Board and (ii) $7,500 ($20,000 for Chair), $7,500 ($20,000 for Chair), $5,000 ($13,750 for Chair) and $4,750 ($10,000 for Chair) to each non-employee director that serves as a member of the Audit Committee, Finance Committee, Compensation Committee, and/or Nominating and Corporate Governance Committee, respectively (collectively, the “Committee Grant”).  For continuing (incumbent) non-employee directors, the Board Grant and, where applicable, any Committee Grant shall be granted as of the date of the annual meeting of stockholders, based upon the volume-weighted average price of the Company’s stock for the 30-trading day period prior to the grant date. For newly elected or newly appointed, non-employee directors and/or for newly appointed committee Chairpersons and members, the Board Grant and, where applicable, any Committee Grant shall be granted upon election or appointment to the Board or Board committee, with a grant value, as determined by the 30-trading day period prior to date of election or appointment, pro-rated by the number of days from the date of the prior annual meeting of stockholders to the date of the grant, divided by 365.  In each case, the Board Grant and any Committee Grant shall vest on the earlier of (a) the twelve (12)-month anniversary of the grant date and (b) the death or resignation of the director.  In the event of death or resignation of the director, the Board Grant and any Committee Grant shall vest pro-rated based on the number of actual days served by the director from the time of the grant to such death or resignation, divided by 365.

In addition, it is anticipated that Mr. Pelizzon will enter into the Company’s standard form of indemnification agreement for non-employee directors, a copy of which is attached as Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, filed with the Securities and Exchange Commission on May 5, 2009, and incorporated herein by reference.

There are no other arrangements or understandings between Mr. Pelizzon and any other person to which he was selected to serve on the Board. There are no family relationships between Mr. Pelizzon and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed to Item 404(a) of Regulation S-K.

On June 17, 2020, the Company held its Annual Meeting of stockholders (the “Annual Meeting”).  The Company filed its definitive proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2020.  The proxy statement describes in detail each of the four proposed voting matters (the “Proposals”) submitted to the Company’s stockholders at the Annual Meeting.  As of April 20, 2020, the record date of the Annual Meeting, there were 63,414,384 outstanding shares of the Company’s common stock. At the Annual Meeting, a quorum of 47,606,090 shares of the Company’s common stock were represented in person or by proxy.  The final results for the votes cast with respect to each Proposal are set forth below.

Proposal 1

The stockholders elected each of Evan Bakst, Mortimer Berkowitz III, Quentin Blackford, Jason Hochberg, Karen K. McGinnis, Patrick S. Miles, David H. Mowry, Jeffrey P. Rydin, James L.L. Tullis, Donald A. Williams and Ward W. Woods to serve on the Company’s Board for a term of one year until the 2021 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified, or until their earlier death or resignation, by the following vote:

Proposal 2

The stockholders ratified the selection of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2020 by the following vote:

Proposal 3

The stockholders approved the amendment of the Company’s 2016 Equity Incentive Plan by the following vote:

Proposal 4

The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executed officers by the following vote:

No other items were presented for stockholder approval at the Annual Meeting.

Alphatec Holdings, Inc. Exhibit
EX-10.1 2 atec-ex101_6.htm EX-10.1 atec-ex101_6.htm Exhibit 10.1 FOURTH AMENDMENT TO THE ALPHATEC HOLDINGS,…
To view the full exhibit click here

About ALPHATEC HOLDINGS, INC. (NASDAQ:ATEC)

Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.

An ad to help with our costs